Outcomes of Primary Trabeculectomy in Secondary Glaucoma with Cytomegalovirus Anterior Uveitis
Gulce Kayikci Mahmutoglu, Burcu Kemer Atik, Cigdem Altan, Berru Yargi Ozkocak, Berna Basarir, Nese Alagoz, Tekin YasarPrécis:
In eyes with CMV anterior uveitis–associated glaucoma, primary trabeculectomy with mitomycin C achieved a 92% success rate over a 4-year follow-up, providing sustained intraocular pressure control and reducing the frequency of uveitic attacks.
Purpose:
To evaluate long-term efficacy, safety, and complications of mitomycin C (MMC)-augmented trabeculectomy (TRAB) in eyes with cytomegalovirus anterior uveitis (CMV AU)–associated secondary glaucoma.
Methods:
This retrospective study included 25 eyes of 25 patients with CMV-AU undergoing primary TRAB with MMC. Success was defined as IOP 5-21 mmHg without systemic acetazolamide or further surgery. Complete success required no topical medication, while qualified success allowed it. Kaplan-Meier survival analysis was used to evaluate success rates.
Results:
Mean follow-up was 45.7±17.8 months. Preoperative IOP (36.0±9.0 mmHg) decreased significantly to 12.2±4.7 mmHg at the final visit (
Conclusions:
Primary TRAB with MMC is a safe and effective strategy for CMV-AU associated glaucoma, reducing IOP and medication burden while preserving visual acuity. However, vigilance is required regarding early hypotony and the potential need for additional postoperative interventions.